PharmaEngine (4162) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 智擎

PharmaEngine (4162) reported revenue of NT$22.5 million for Oct 2026, -18.3% year on year and -89.9% from the previous month. Revenue for Jan–Oct 2026 was NT$787.8 million (+20.5% year on year).

In Oct 2026, it ranked No. 121 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$22.1 million24/10Nov 2024 NT$23.1 millionDec 2024 NT$1.83 billionJan 2025 NT$23.4 millionFeb 2025 NT$18.2 million25/02Mar 2025 NT$145.8 millionApr 2025 NT$24.5 millionMay 2025 NT$18.5 millionJun 2025 NT$153.7 million25/06Jul 2025 NT$22.4 millionAug 2025 NT$22.2 millionSep 2025 NT$197.6 millionOct 2025 NT$27.6 million25/10Nov 2025 NT$30 millionDec 2025 NT$227.5 millionJan 2026 NT$72.2 millionFeb 2026 NT$13.1 million26/02Mar 2026 NT$154.5 millionApr 2026 NT$24 millionMay 2026 NT$28.2 millionJun 2026 NT$205.9 million26/06Jul 2026 NT$23.3 millionAug 2026 NT$20.6 millionSep 2026 NT$223.4 millionOct 2026 NT$22.5 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$22.5 million-18.3%-89.9%
Sep 2026NT$223.4 million+13.1%+982.1%
Aug 2026NT$20.6 million-7.0%-11.5%
Jul 2026NT$23.3 million+4.4%-88.7%
Jun 2026NT$205.9 million+33.9%+631.2%
May 2026NT$28.2 million+51.9%+17.3%
Apr 2026NT$24 million-2.1%-84.5%
Mar 2026NT$154.5 million+6.0%+1,080.9%
Feb 2026NT$13.1 million-28.1%-81.9%
Jan 2026NT$72.2 million+208.3%-68.3%
Dec 2025NT$227.5 million-87.6%+657.6%
Nov 2025NT$30 million+29.9%+8.9%
Oct 2025NT$27.6 million+24.7%-86.0%
Sep 2025NT$197.6 million+18.4%+790.2%
Aug 2025NT$22.2 million-14.7%-0.7%
Jul 2025NT$22.4 million-11.9%-85.5%
Jun 2025NT$153.7 million-0.2%+729.3%
May 2025NT$18.5 million-78.6%-24.4%
Apr 2025NT$24.5 million+16.2%-83.2%
Mar 2025NT$145.8 million+22.6%+701.5%
Feb 2025NT$18.2 million-2.8%-22.3%
Jan 2025NT$23.4 million-12.8%-98.7%
Dec 2024NT$1.83 billion+1,148.7%+7,830.9%
Nov 2024NT$23.1 million+8.9%+4.5%
Oct 2024NT$22.1 million+14.8%-86.7%

Jan–Oct 2026 cumulative: NT$787.8 million (+20.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: PharmaEngine vs PEC / PharmaEngine vs Lotus Pharm / PharmaEngine vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16